GSK buys US skincare company Stiefel
Monday 20th April 2009, 11:47AM BST.
The UK’s biggest pharmaceutical company Glaxo Smith Kline (GSK) has announced a $3.6 billion (£2.5 million) deal to buy US skincare company Stiefel.
Andrew Witty, GSK’s chief executive officer, said: “This transaction will create a new world-leading, specialist dermatology business and re-energise our existing dermatology products.
“The addition of Stiefel’s broad portfolio will provide immediate new revenue flows to GSK with significant opportunities to enhance growth through leveraging our existing global commercial infrastructure and manufacturing capability.
“We look forward to working with Stiefel to develop this exciting opportunity.”
Steifel specialises in treatments for acne and psoriasis. Its sales were $900 million last year, which combined with GSK’s $550 million will give the new business an eight per cent share of the prescription skincare market.
When the deal is completed later this year, the new company will be led by Charles Stiefel, current head of the US company.
The deal comes just days after GSK announced an agreement with New York based pharmaceutical company Pfizer to merge the two companies’ HIV drug businesses. The new company will have a 20 per cent share of the market providing vital drugs to HIV sufferers.
Shropshire Star on Twitter
Keep updated with the latest breaking news and content on our Twitter feed.
Lifestyle
Interactive Dining Out map
Hundreds of reviews by the Shropshire Star and Express & Star's teams to help you decide where to eat.
Entertainment
All the film reviews
Before you plan a trip to the pictures, get our critics' verdicts on all the latest movie releases.
OUR NEW APP
Get the new Shropshire Star app
Download the Shropshire Star’s new app to your iPad or iPhone to get one week of access to our digital newspapers absolutely FREE.
shropshirestar.com
Popular sections
Useful links
